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MATERIALS AND METHODS

PBPC Mobilization
Four-week-old male (CS7BL/6J X DBA/2J) F, mice (Charles River Laboratories, Wilmington, MA) were splenectomized and housed under sterile conditions until they reached 10 weeks of age. The mice were injected intravenously with rrSCF-PEG, rhG-CSF, or the combination of both cytokines daily for 7 days. Each experiment also contained a group of mice treated only with the carrier, consisting of I % bovine serum albumin (Sigma Chemical CO, St Louis, MO) suspended in isotonic saline.
Cell Harvesting
Peripheral blood was harvested by cardiac puncture and collected into EDTA-containing tubes. Bone marrow cells were harvested by flushing the contents of the femur with 1 mL of Hanks' Balanced Salt Solution (HBSS; GIBCO Laboratories, Life Technologies, Inc; Grand Island, NY) containing 2% fetal bovine serum (Flow Laboratories, Inc, McLean, VA). The numbers of WBC, red blood cells (RBC), and platelets in the peripheral blood were determined using a Sysmex Microcellcounter (Baxter Healthcare Corp, Irvine, CA). Bone marrow WBC numbers were determined by staining with crystal violet and subsequently enumerated on a hemacytometer.
Peripheral Blood Density Gradient Fractionation
Peripheral blood was pooled from all mice in each treated group and layered over single Nycodenz density gradients of I . 167 g/mL (Accurate Chemical and Scientific Corp, Westbury, NY). The lowdensity (LD) cells were harvested, washed, and resuspended in the camer. These LD cells were then used in the progenitor cell assays and the PBPC transplantation.
Growth Factors
ITSCF-PEG: rhC-CSF,9 rrSCF," recombinant human interleukin-6 (rhlL-6)," and recombinant human erythropoietin (rhEpo)'* were obtained from Amgen Inc (Thousand Oaks, CA). rrSCF-PEG has been shown to be required for activity in in vivo studies with rodents because the unpegylated form has little in vivo activity (McNiece IK and Zsebo KM, unpublished data). Recombinant murine IL-3 (rmIL-3)" was obtained from PeproTech Inc (Rocky Hill, NJ). All factors were purified to greater than 99% punty.
Progenitor Cell Assays
Both 2.5 x lo4 and 1.0 X lo5 LD cells were cultured in a double-layer agar-based assay system in triplicate, as previously described.14 Each culture contained optimal doses of rrSCF (100 ng/culture), rmIL-3 (2.5 ng/culture), and GM-CFC and HPP-CFC. 
PBPC Transplantation
Twelve-week-old female (C57BL/6J X DBA/2J) F, mice (Charles River Laboratories) were irradiated at 1,150 rad using a cesium source, which was administered as a split-dose of equal intensity 4 hours apart. Mice were injected intravenously with the camer or various numbers of LD cells 4 hours after the second irradiation. All experiments contained irradiation controls, in which 10 mice were irradiated without LD cell transplantation to show the lethality of the irradiation dose.
RESULTS
A dose-related increase in peripheral blood WBC numbers resulted with a daily injection of rrSCF-PEG for 7 days (Table 1 ). Approximately 9.0 X l o 7 WBC/mL ofperipheral blood were obtained in mice treated with 200 pg/kg of rrSCF-PEG compared with approximately 2.0 X l o 7 in mice receiving only the camer (Table 1) . Both primitive (HPP-CFC) and mature (GM-CFC) progenitor cell numbers were increased with a plateau occurring at doses of 100 and 200 pg/kg ( Table 1) . A total of 2.0 X IO5 LD cells were transplanted into lethally irradiated recipients to determine the transplant potential of the mobilized PBPC. Maximal survival was obtained with cells from mice treated with 200 pg/kg with a dose-related decrease in survival, as shown in Table 1 .
To further evaluate the potential of high doses of rrSCF-PEG to mobilize PBPC, mice were treated with 200 pg/kg/d for 7 days, and decreasing numbers of cells were transplanted into lethally irradiated mice. Treatment with rrSCF-PEG resulted in increased WBC numbers, with a small decrease in platelets and no significant change in RBC numbers. No significant change was observed in the WBC numbers in the bone marrow of these mice. Transplantation of 1.0 X lo', 5.0 X lo6, or 2.5 X lo6 LD cells from untreated animals resulted in loo%, 20%, and 10% survival of irradiated mice, respectively, whereas 2.5 X lo5, 5.0 X lo5, or 1.0 X lo6 LD cells from rrSCF-PEG treated mice all resulted in 100% survival. This represents a 40-fold higher number of cells capable of rescuing lethally irradiated mice in the peripheral blood of rrSCF-PEG-treated mice as compared with untreated mice.
Based on the ability of low doses of rhSCF to synergize with other hematopoietic cytokines in vitro, including rhG-CSF, we examined the potential of low doses of rrSCF-PEG to synergize with rhG-CSF in PBPC mobilization. No significant increase in WBC numbers was obtained with rrSCF-PEG treatment compared with untreated mice, whereas rhG-CSF stimulated more than twofold higher WBC numbers ( Table 1 and Fig 1) . The combination of rrSCF-PEG and rhG-CSF stimulated a synergistic increase in WBC numbers (Fig 1) . No significant differences were obtained for bone marrow WBC numbers (Fig 1) .
In mice treated with both rrSCF-PEG and rhG-CSF, an approximately threefold increase per 100,000 LD cells in mature progenitor cells (GM-CFC) resulted compared with rhG-CSF alone (Fig 2) . Only a slight increase in primitive progenitor cells (HPP-CFC) was obtained in this setting (Fig  2) . However, when corrected for the WBC number increases alone or in combination for 7 days. LD cells were cultured in a double-layer agar-based assay system in triplicate. Each culture contained optimal doses of rrSCF (100 ng/mL), rmlL-3 (2.5 ng/mL), and rhlL-6 (1 00 ng/mL), and was incubated for 14 days.
obtained with the combination rrSCF-PEG and rhG-CSF over rhG-CSF alone, significantly higher absolute numbers of HPP-CFC were released by the combination (Table 2) . Similarly, whereas only a slight increase in the incidence of erythroid progenitor cells (BFU-E) was obtained with rrSCF-PEG and rhG-CSF as compared with rhG-CSF alone, the absolute numbers of BFU-E were greatly increased (data not shown). Transplantation of the mobilized PBPC from rrSCF-PEG plus rhG-CSF-treated animals resulted in equivalent or greater survival of lethally irradiated mice compared with animals receiving transplants of rhG-CSF-mobilized PBPC (Table 3) . When corrected for the increased WBC count, the combination of KSCF-PEG plus rhG-CSF resulted in an absolute increase in the number of cells capable of rescuing lethally irradiated mice compared with rhG-CSF alone. * Splenectomized mice (n = IO) were treated with the growth factors shown for 7 days, at which time peripheral blood was harvested and LD cells were fractionated and cultured as described in the Materials and Methods.
t Absolute GM-CFC and HPP-CFC numbers were calculated by multiplying the mean colony numbers per 1 .O X lo5 cells (from Fig 2) by the WBC numbers (from Fig 1) and dividing by 1 .O X 1 05. This represents an approximation of total GM-CFC and total HPP-CFC per milliliter peripheral blood after factor treatment. 
DISC US S IO N
The use of G-CSF for PBPC mobilization for support of high-dose chemotherapy has enabled more rapid engraftment of both neutrophils and platelet^.^ However, a significant period of neutropenia and thrombocytopenia still occurs with PBPC transplantation. Other means of mobilization, including chemotherapy and/or growth factors such as GM-CSF or IL-3, result in nonoptimal mobilization. Current protocols require at least three aphereses to collect enough cells for transplantation. In a number of patients, insufficient numbers of CD34' and/or GM-CFC in the harvest make them ineligible for transplantation. Further data presented in this study show the potential of the combination of SCF plus G-CSF to mobilize PBPC. The combination of low doses of rrSCF-PEG (25 pg/kg) plus rhG-CSF (200 pg/kg) results in a synergistic increase in circulating WBC numbers, GM-CFC, BFU-E, HPP-CFC, and cells capable of rescuing lethally irradiated mice, as compared with mobilization with rhG-CSF alone. The low dose of rrSCF-PEG has little, if any, effect alone. The effective dose of rhG-CSF in clinical treatment is at least 1 log lower in humans than the optimal dose in mice. If an equivalent ratio occurs with SCF, the range of 2.5 to 5.0 pg/kg may be an effective dose in combination with G-CSF. In early clinical studies, SCF has been reported to be well tolerated at 10 pg/kg,'8*'9 suggesting that a dose of 2.5 to 5 pg/kg will be well tolerated by patients. The data presented in this study suggest that the combination will be effective in mobilizing PBPC.
In summary, this study presents data supportive of a role of low doses of SCF in combination with G-CSF for enhanced mobilization of PBPC. The data suggest that clinical trials with this combination may result in fewer apheresis harvests and, possibly, better engraftment.
